Novel Oral Agent Proves Mettle in Obstructive Hypertrophic Cardiomyopathy

(MedPage Today) — MADRID — The novel oral cardiac myosin inhibitor aficamten improved exercise capacity and symptoms of obstructive hypertrophic cardiomyopathy (HCM) better than standard beta-blocker treatment, the MAPLE-HCM randomized trial…